Zynerba Pharmaceuticals Stock Target Price
ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
Zynerba Pharmaceuticals fundamentals help investors to digest information that contributes to Zynerba Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zynerba Stock. The fundamental analysis module provides a way to measure Zynerba Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zynerba Pharmaceuticals stock.
Zynerba |
Zynerba Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zynerba Pharmaceuticals' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zynerba Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zynerba Pharmaceuticals by comparing valuation metrics of similar companies.Zynerba Pharmaceuticals is currently under evaluation in target price category among its peers.
Zynerba Fundamentals
Return On Equity | -0.87 | |||
Return On Asset | -0.45 | |||
Current Valuation | 28.33 M | |||
Shares Outstanding | 53.94 M | |||
Shares Owned By Insiders | 6.07 % | |||
Shares Owned By Institutions | 12.12 % | |||
Number Of Shares Shorted | 419.98 K | |||
Price To Earning | (3.84) X | |||
Price To Book | 0.54 X | |||
Price To Sales | 1,153 X | |||
EBITDA | (34.62 M) | |||
Net Income | (35.04 M) | |||
Cash And Equivalents | 62.49 M | |||
Cash Per Share | 1.44 X | |||
Total Debt | 334.43 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 6.89 X | |||
Book Value Per Share | 0.57 X | |||
Cash Flow From Operations | (23.03 M) | |||
Short Ratio | 0.26 X | |||
Earnings Per Share | (0.80) X | |||
Target Price | 1.25 | |||
Number Of Employees | 25 | |||
Beta | 1.19 | |||
Market Capitalization | 70.12 M | |||
Total Asset | 55.52 M | |||
Retained Earnings | (274.52 M) | |||
Working Capital | 45.6 M | |||
Current Asset | 43.42 M | |||
Current Liabilities | 3.94 M | |||
Net Asset | 55.52 M |
About Zynerba Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zynerba Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zynerba Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zynerba Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |